Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospitals Coventry and Warwickshire NHS Trust
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
M.D. Anderson Cancer Center
University Health Network, Toronto
Mayo Clinic
M.D. Anderson Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
M.D. Anderson Cancer Center
University of Washington
Sun Yat-sen University
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Tianjin Medical University Cancer Institute and Hospital
Vanderbilt-Ingram Cancer Center
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
University of California, Irvine
Thomas Jefferson University
Vanderbilt-Ingram Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sichuan University
Universitätsmedizin Mannheim
Humanetics Corporation
Swiss Cancer Institute
Sichuan University
Spanish Lung Cancer Group
Nanfang Hospital, Southern Medical University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Alliance for Clinical Trials in Oncology
Amsterdam UMC, location VUmc
Swiss Cancer Institute
Fox Chase Cancer Center
University of Pittsburgh
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences